16929-64-9

Basic information

• Product Name: 1,3-dimethoxy-2-propylbenzene
• Synonyms: 1,3-dimethoxy-2-propylbenzene;1,3-DiMethoxy-2-(prop-1'-yl)benzene;Benzene,1,3-dimethoxy-2-propyl-
• CAS NO: 16929-64-9
• Molecular Formula: C₁₁H₁₆O₂
• Molecular Weight: 180.24354
• Mol File: 16929-64-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 241.2°C at 760 mmHg
• Flash Point: 83.3°C
• Appearance: /
• Density: 0.965g/cm³
• Vapor Pressure: 0.0563mmHg at 25°C
• Refractive Index: 1.487
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,3-dimethoxy-2-propylbenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dimethoxy-2-propylbenzene(16929-64-9)
• EPA Substance Registry System: 1,3-dimethoxy-2-propylbenzene(16929-64-9)

Safety Data

• Hazardous Substances Data: 16929-64-9(Hazardous Substances Data)

Usage

General Description

1,3-dimethoxy-2-propylbenzene, also known as eugenol, is a chemical compound found in cloves as well as other essential oils. It has a powerful, spicy, and clove-like aroma and is commonly used in perfumes, flavorings, and as a dental analgesic. It is a colorless to pale yellow liquid with a molecular formula of C12H16O2 and a boiling point of 254°C. Eugenol is widely used in the food and pharmaceutical industries for its antiseptic, antioxidant, and anti-inflammatory properties. It is also used in the production of insect attractants and repellents, as well as in the synthesis of various organic compounds. Additionally, eugenol has been studied for its potential anti-cancer and anti-microbial properties.

InChI:InChI=1/C11H16O2/c1-4-6-9-10(12-2)7-5-8-11(9)13-3/h5,7-8H,4,6H2,1-3H3

Upstream product

• 107-08-4 1-iodo-propane 
• 151-10-0 1,3-Dimethoxybenzene 

Downstream Products

• 13331-19-6 2-propyl-1,3-benzenediol 
• 118684-06-3 2,4-dimethoxy-3-propylbromobenzene 
• 93114-94-4 3-methoxy-2-propylphenol 
• 40786-69-4 1-(2,4-dihydroxy-3-propylphenyl)ethanone 
• 1186116-57-3 5-(4-hydroxyphenyl)-5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione 
• 1186116-02-8 4-(4-methyl-2,5-dioxo-1-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidin-4-yl)benzoic acid 
• 1186116-03-9 5-(3,4-dimethoxyphenyl)-5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione 
• 1186116-08-4 5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)-butyl)-5-phenylimidazolidine-2,4-dione 
• 1186115-79-6 5-(4-methoxyphenyl)-5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione 
• 79558-49-9 2,4-dihydroxy-3-propylphenyl ethyl ketone 
• 118683-34-4 4-(3-Hydroxy-4-phenylcarbamoyl-2-propyl-phenoxymethyl)-3-methoxy-benzoic acid 
• 118683-27-5 4-(4-Hexanoyl-3-hydroxy-2-propyl-phenoxymethyl)-3-methoxy-benzoic acid 
• 118684-12-1 2-tetrahydropyranyl 4-<<4-(trifluoroacetyl)-3-hydroxy-2-propylphenoxy>methyl>benzoate 
• 118683-37-7 4-(3-Hydroxy-2-propyl-4-quinolin-2-yl-phenoxymethyl)-3-methoxy-benzoic acid 

Relevant articles and documents

Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists

In an attempt to molecularly design liver X receptor (LXR) β-selective agonists, we discovered that the combination of the 2-oxochromene moiety (head) and the imidazoline-2,4-dione moiety (tail) plays an important role in the expression potency and select

Synthetic and structure/activity studies on acid-substituted 2- arylphenols: Discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist

Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These new analogues, the subject of a broad structure-activity investigation, displayed significantly increased in vitro and in vive activity as receptor antagonists of LTB4. A series of diaryl ether carboxylic acids demonstrated especially interesting activity and led to the discovery of compound 43b, 2- [2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]- propoxy]phenoxy]benzoic acid (LY293111), a 2-arylphenol-substituted diaryl ether carboxylic acid which displayed potent binding to human neutrophils (IC50 = 17 ± 4.6 nM) and guinea pig lung membranes (IC50 = 6.6 ± 0.71 nM), inhibition of LTB4-induced expression of the CD11b/CD18 receptor on human neutrophils (IC50 = 3.3 ± 0.81 nM), and inhibition of LTB4-induced contraction of guinea pig lung parenchyma (pK(B) = 8.7 ± 0.16). In vivo, 43b demonstrated potent activity in inhibiting LTB4-induced airway obstruction in the guinea pig when dosed by the oral (ED50 = 0.40 mg/kg) or intravenous (ED50 = 0.014 mg/kg) routes. A specific LTB4 receptor antagonist, 43b had little effect on inhibiting contractions of guinea pig lung parenchyma induced by leukotriene D4 (LTD4), histamine, carbachol, or U46619. Compound 43b has been chosen as a clinical candidate and is currently in phase I studies for a variety of inflammatory diseases.

USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE

This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amount of an inhibitor of phospholipase A2. This invention also provides a series of compounds which are useful as inhibitors of phospholipases A2, especially cytosolic phospholipase A2.